@spontonic.bsky.social
Posts OFTEN do not relate to portfolio, and retweets do not imply endorsement. Ph.D. immunogenetics from.... http://mimg.ucla.edu
#CHRS #ZLAB many others..... a non-oncology indication for anti- #CCR8? pubmed.ncbi.nlm.nih.gov/40350095/
Expansion of multiple CD4+ T cell lineages in lymphocytic variant hypereosinophilic syndrome - PubMed
These data provide further evidence for direct involvement of the aberrant T cell populations in disease pathogenesis in LHES and a rationale for further exploration of T cell-directed therapies.
pubmed.ncbi.nlm.nih.gov
May 26, 2025 at 11:36 PM
#CHRS #ZLAB many others..... a non-oncology indication for anti- #CCR8? pubmed.ncbi.nlm.nih.gov/40350095/
"CCL1/ #CCR8 may be the pathway between NECs and Tregs in vitro and may play a key role in the immune network of AR"... pmc.ncbi.nlm.nih.gov/articles/PMC...
Interaction between nasal epithelial cells and Tregs in allergic rhinitis responses to allergen via CCL1/CCR8
The airway epithelial barrier is the first defence against aeroallergens. Nasal epithelial cells (NECs) are vital in regulating innate and adaptive mucosal immunity in allergic rhinitis (AR). Tregs pr...
pmc.ncbi.nlm.nih.gov
March 10, 2025 at 7:43 PM
"CCL1/ #CCR8 may be the pathway between NECs and Tregs in vitro and may play a key role in the immune network of AR"... pmc.ncbi.nlm.nih.gov/articles/PMC...
#CHRS #BMY #ZLAB #CCR8 LM-108? >>depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the JAK-STAT pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells<< www.sciencedirect.com/science/arti....
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in non-small cell lung cancer (NSCLC)…
www.sciencedirect.com
March 7, 2025 at 4:16 PM
#CHRS #BMY #ZLAB #CCR8 LM-108? >>depletion of CCR8+Treg cells combined with PD1 inhibitor extremely increased interleukin-12 secretion by the JAK-STAT pathway activation on CCL5+ DCs, thereby promoting cytotoxic activity of CD8+ T cells<< www.sciencedirect.com/science/arti....
#CHRS Another alternative for casdo? "Our results suggest that IL-27 is detrimental in the acute stage of cerebral infarction." www.sciencedirect.com/science/arti...
Interleukin-27 deletion has neuroprotective effects in the acute ischemic stage of cerebral infarction
Post-ischemic inflammation is an essential step in the progression of brain ischemia-reperfusion injury. Cytokines such as interleukins 17 and 23 (IL-…
www.sciencedirect.com
March 4, 2025 at 12:10 AM
#CHRS Another alternative for casdo? "Our results suggest that IL-27 is detrimental in the acute stage of cerebral infarction." www.sciencedirect.com/science/arti...
Publications are being weaponized, cited incorrectly by those who know better (or could know better with a minute of unbiased searching).
February 26, 2025 at 7:40 PM
Publications are being weaponized, cited incorrectly by those who know better (or could know better with a minute of unbiased searching).
Immuno Precise Antibodies... LOL. I guess, as a service function, it might work. If your company/lab has no molecular biologists and serologists, go to these guys. Otherwise, buy a mouse and let it do the work. finance.yahoo.com/news/ipa-rib...
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
AUSTIN, Texas, February 26, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announced a strategic co...
finance.yahoo.com
February 26, 2025 at 7:26 PM
Immuno Precise Antibodies... LOL. I guess, as a service function, it might work. If your company/lab has no molecular biologists and serologists, go to these guys. Otherwise, buy a mouse and let it do the work. finance.yahoo.com/news/ipa-rib...
#CHRS Haven't visited ILT4 in ages. "Tumor-Derived Immunoglobulin-Like Transcript 4 Promotes Postoperative Relapse via Inducing Vasculogenic Mimicry through MAPK/ERK Signaling in Hepatocellular Carcinoma" pubmed.ncbi.nlm.nih.gov/39233275/
Tumor-Derived Immunoglobulin-Like Transcript 4 Promotes Postoperative Relapse via Inducing Vasculogenic Mimicry through MAPK/ERK Signaling in Hepatocellular Carcinoma - PubMed
The efficacy of conventional anti-angiogenesis drugs is usually low in treating hepatocellular carcinoma (HCC). Therefore, there is an urgent need to find new precise therapeutic targets and to develo...
pubmed.ncbi.nlm.nih.gov
February 26, 2025 at 4:54 PM
#CHRS Haven't visited ILT4 in ages. "Tumor-Derived Immunoglobulin-Like Transcript 4 Promotes Postoperative Relapse via Inducing Vasculogenic Mimicry through MAPK/ERK Signaling in Hepatocellular Carcinoma" pubmed.ncbi.nlm.nih.gov/39233275/
mRCC.... "Regarding progression-free survival and overall survival, combined Toripalimab + Axitinib significantly outperformed other immunotherapy-based combination therapies"... www.sciencedirect.com/science/arti...
Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: A network meta-analysis
Despite numerous meta-analyses comparing the efficacy and safety of immunotherapy-based combination therapies, the optimal therapeutic combinations re…
www.sciencedirect.com
February 8, 2025 at 5:56 PM
mRCC.... "Regarding progression-free survival and overall survival, combined Toripalimab + Axitinib significantly outperformed other immunotherapy-based combination therapies"... www.sciencedirect.com/science/arti...
Conversion of unresectable NSCLC to resectable, toripalimab plus chemo..... www.cell.com/med/abstract...
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Zeng et al. demonstrated the potential efficacy of perioperative toripalimab combined
with platinum-doublet chemotherapy in converting unresectable stage IIIA–IIIB NSCLC
to resectable disease. The reg...
www.cell.com
February 8, 2025 at 5:50 PM
Conversion of unresectable NSCLC to resectable, toripalimab plus chemo..... www.cell.com/med/abstract...
Surufatinib (TKI that targets VEGFR, FGFR1, and CSF1R) plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer.... ORR = 57%. link.springer.com/article/10.1...
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, ...
Background Combining the programmed death-1 inhibitor toripalimab and the angio-immuno kinase inhibitor surufatinib showed preliminary antitumor activity in patients with advanced solid tumors in a ph...
link.springer.com
February 8, 2025 at 5:45 PM
Surufatinib (TKI that targets VEGFR, FGFR1, and CSF1R) plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer.... ORR = 57%. link.springer.com/article/10.1...
Anti-LAG-3 plus toripalimab, pecking around edges of NPC, not particularly effective relative to tori alone. Horrid for some other histologies. jhoonline.biomedcentral.com/articles/10....
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial - Journal of Hematology & Onc...
Purpose Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced na...
jhoonline.biomedcentral.com
February 8, 2025 at 5:22 PM
Anti-LAG-3 plus toripalimab, pecking around edges of NPC, not particularly effective relative to tori alone. Horrid for some other histologies. jhoonline.biomedcentral.com/articles/10....
Exactly opposite of what early #casdo results might imply, HCC.... In mice, "IL-27 receptor agonism can safely improve anti-tumour T cell responses alone or in combination with PD-L1 blockade" www.nature.com/articles/s41...
IL-27 elicits a cytotoxic CD8+ T cell program to enforce tumour control - Nature
IL-27 promotes tumour control by preventing dysfunction and enhancing cytotoxicity of tumour-specific CD8+ T cells.
www.nature.com
February 8, 2025 at 1:12 AM
Exactly opposite of what early #casdo results might imply, HCC.... In mice, "IL-27 receptor agonism can safely improve anti-tumour T cell responses alone or in combination with PD-L1 blockade" www.nature.com/articles/s41...
Casdo, obesity and #CHRS. Nothing but teaser here, but may follow up on the manuscript by Du et al. which I pointed to earlier. www.frontiersin.org/journals/imm...
Frontiers | Revisiting the role of IL-27 in obesity-related metabolic diseases: Safeguard or perturbation?
The prevalence of metabolic diseases, such as obesity, has been steadily increasing in recent years, posing a significant threat to public health. Therefore,...
www.frontiersin.org
January 1, 2025 at 11:43 PM
Casdo, obesity and #CHRS. Nothing but teaser here, but may follow up on the manuscript by Du et al. which I pointed to earlier. www.frontiersin.org/journals/imm...
Haematopoietic gene therapy effectively reversed bone marrow failure in Fanconi anaemia patients without severe complications.
by Río P, Zubicaray J (...) Bueren JA et 36 al. in Lancet #MedSky
📖 read the article: https://linkinghub.elsevier.com/retrieve/pii/S0140673624018804
by Río P, Zubicaray J (...) Bueren JA et 36 al. in Lancet #MedSky
📖 read the article: https://linkinghub.elsevier.com/retrieve/pii/S0140673624018804
December 12, 2024 at 8:59 PM
IL-27 catabolism.... Casdo "increases circulating IL-27 in a dose-dependent manner, consistent with the antibody binding to its target and preventing cytokine clearance" #CHRS www.coherus.com/wp-content/u...
www.coherus.com
December 12, 2024 at 4:47 PM
IL-27 catabolism.... Casdo "increases circulating IL-27 in a dose-dependent manner, consistent with the antibody binding to its target and preventing cytokine clearance" #CHRS www.coherus.com/wp-content/u...
#CHRS #BMY #ZLAB LaNova licenses anti- #CCR8 LM-108 in China. Together with #MRK deal for LM-299 (PD-1/VEGF, $588m upfront), LaNova is swimming in cash. Who will get the U.S. license for 108? en.zhonglun.com/news/trade/5...
The official website of Zhong Lun Law Firm
中伦律师律所官方网站
en.zhonglun.com
November 27, 2024 at 5:17 PM
#CHRS I value CHS-114 at $100m, and believe that valuation could increase rapidly by #ASCO25. Dr. LaVallee, at the last quarterly call, said that they consider recent results from LaNova to establish POC for anti-CCR8. This is a good primer... www.oncologypipeline.com/apexonco/ccr...
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
www.oncologypipeline.com
November 26, 2024 at 6:15 PM
#CHRS I value CHS-114 at $100m, and believe that valuation could increase rapidly by #ASCO25. Dr. LaVallee, at the last quarterly call, said that they consider recent results from LaNova to establish POC for anti-CCR8. This is a good primer... www.oncologypipeline.com/apexonco/ccr...
#CHRS I value casdozokitug at $150m, going to $0-300m by #ASCO25. This is pretty much everything we know.... www.oncologypipeline.com/apexonco/asc...
ASCO-GI – early casdozokitug celebration for Coherus
www.oncologypipeline.com
November 26, 2024 at 6:05 PM
#CHRS I value casdozokitug at $150m, going to $0-300m by #ASCO25. This is pretty much everything we know.... www.oncologypipeline.com/apexonco/asc...
Testing, testing..... $CHRS Does the dollar sign work to link various posts to a given ticker, as at the competitor site?? Is #DennyLanfear the worst CEO on the planet, or what??
November 24, 2024 at 4:27 PM
Testing, testing..... $CHRS Does the dollar sign work to link various posts to a given ticker, as at the competitor site?? Is #DennyLanfear the worst CEO on the planet, or what??